Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multi-organ quantitative proteome map following ASNase treatment

ABSTRACT: We applied the ultra-fast proteome profiling workflow to tissues collected from NSG mice treated with PBS (vehicle control), 20,000 U/kg ASNaseWT (Spectrila®), or 20,000 U/kg ASNaseQ59L for 0, 1, 3, 5, and 8 d. At each time point, mice were euthanized, and 13 tissues were collected, including subcutaneous white adipose tissue (SQWAT), gonadal adipose tissue (GAT), lung, spleen, stomach, small and large intestine, liver, kidney, heart, leg muscle, brain, and bone marrow. A total of 507 collected tissue samples were processed for quantitative proteome profiling.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Whole Body

SUBMITTER: Yun Xiong

LAB HEAD: Philip L. Lorenzi

PROVIDER: PXD055590 | Pride | 2026-01-14

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	052624_nDIA_2m_SysBio_10_Heart_1.raw	Raw
	052624_nDIA_2m_SysBio_10_Heart_10.raw	Raw
	052624_nDIA_2m_SysBio_10_Heart_11.raw	Raw
	052624_nDIA_2m_SysBio_10_Heart_12.raw	Raw
	052624_nDIA_2m_SysBio_10_Heart_13.raw	Raw

Items per page:

1 - 5 of 527

Similar Datasets

Cdn-Cna1-GFP-IP from Cryptococcus neoformans, Yadav and Heitman

Project description:Differential protein interaction analysis following IP, LC-MS/MS, and label-free quantitation on an Orbitrap Astral

2025-08-21 | PXD060167 | Pride

Differential interaction proteomics and phosphoproteomics of STK17B on an Oribtrap Astral, Nikiforov

Project description:LC-MS based DIA label free analysis of trubo-ID driven interaction study

2025-09-05 | PXD068040 | Pride

Supercharging-Enhanced nDIA-MS Enables Global Profiling of Drug-Induced Proteome Solubility Shifts (solubility proteomics)

Project description:Mass spectrometry (MS)-based proteomics has become indispensable for high-throughput quantitation of protein expression. However, protein function is regulated by a variety of factors beyond abundance alone. Here, we optimized narrow-window, data-independent ac-quisition (nDIA) MS with 3% DMSO as a supercharging co-solvent, boosting signal intensity by up to 56% and enabling identification of ~9,600 proteins from 1 µg of HeLa digest with a 15 min gradient. Using this methodology, we quantified solubility and abundance changes in 8,694 pro-teins across three cell lines following short-term treatment with the proteasome inhibitor MG132 and the SUMO-activating enzyme inhibitor ML-792. MG132 affected the solubility of 1,723 pro-teins and the abundance of 374, and ML-792 impacted 1,294 and 288, respectively. The drugs elicited distinct and sometimes opposing solubility shifts; For instance, MG132 insolubilized HSF1, ML-792 solubilized SP100 and insolubilized PLOR3G, and SMAD2 showed opposite responses to those two treatments. These results reveal widespread, drug-induced remodeling of the pro-tein solubility landscape and establish solubility profiling by nDIA-MS as a robust and broadly ap-plicable platform for uncovering protein state transitions and cellular responses to perturbation.

2026-01-12 | PXD064185 | Pride

Supercharging-Enhanced nDIA-MS Enables Global Profiling of Drug-Induced Proteome Solubility Shifts (co-solvent)

Project description:Mass spectrometry (MS)-based proteomics has become indispensable for high-throughput quantitation of protein expression. However, protein function is regulated by a vari-ety of factors beyond abundance alone. Here, we optimized narrow-window, data-independent acquisition (nDIA) MS with 3% DMSO as a supercharging co-solvent, boosting signal intensity by up to 56% and enabling identification of ~9,600 proteins from 1 µg of HeLa digest with a 15 min gradient. Using this methodology, we quantified solubility and abundance changes in 8,694 proteins across three cell lines following short-term treatment with the proteasome in-hibitor MG132 and the SUMO-activating enzyme inhibitor ML-792. MG132 affected the solubil-ity of 1,723 proteins and the abundance of 374, and ML-792 impacted 1,294 and 288, respec-tively. The drugs elicited distinct and sometimes opposing solubility shifts; For instance, MG132 insolubilized HSF1, ML-792 solubilized SP100 and insolubilized PLOR3G, and SMAD2 showed opposite responses to those two treatments. These results reveal wide-spread, drug-induced remodeling of the protein solubility landscape and establish solubility profiling by nDIA-MS as a robust and broadly applicable platform for uncovering protein state transitions and cellular responses to perturbation.

2026-01-11 | PXD064180 | Pride

Mouse Circadian Proteome Atlas by next-generation deep proteome analysis

Project description:The circadian clock drives daily rhythms of gene expression and physiological functions across tissues throughout the body. Advances in next-generation DNA sequencing have provided extensive insights into gene expression at the RNA level, but more functional information at the protein level with sufficient depth has been limited by technical challenges. Recently, the next-generation mass spectrometer Orbitrap Astral was developed, allowing us to quantify protein abundance with greater sensitivity and accuracy. In this study, we generated a comprehensive mouse circadian proteome atlas (available in https://chiba1.dynacom.co.jp/mcp_atlas/) by analyzing protein abundance in 32 tissues including the suprachiasmatic nucleus (SCN) across the day using Orbitrap Astral. Data-independent acquisition of 584 samples including developmental samples revealed the spatiotemporal profiles of 18,956 proteins, accounting for 73.8% of all proteins registered in UniProt. Proteome and phospho-proteome analyses of whole-cell and nuclear proteins in the liver uncovered circadian profiles not only in protein abundance but also in subcellular localization and post-translational modification. Notably, proteome analysis revealed global changes in protein phosphorylation status in hPER2-S662G mutant mice, a genetic model of human familial advanced sleep phase (FASP). This multi-tissue circadian proteome atlas provides a fundamental resource for understanding when, where, and which proteins are expressed and function.

2025-11-27 | PXD069823 | Pride

Mouse Circadian Proteome Atlas by next-generation deep proteome analysis

2025-11-27 | PXD069794 | Pride

SChLAP1 pulldown, Hargrove Lab Duke University

Project description:Test v Control IP of SChLAP1 analyzed by bottoms-up proteomics approach on Orbitrap Astral.

2025-09-08 | PXD055741 | Pride

Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples

Project description:Lysosomes are implicated in a wide spectrum of human diseases including monogenic lysosomal storage disorders (LSDs), age-associated neurodegeneration and cancer. Profiling lysosomal content using tag-based lysosomal immunopurification (LysoIP) in cell and animal models allowed major discoveries in the field, however, studying lysosomal dysfunction in human patients remains a challenge. Here, we report the development of the tagless LysoIP method to enable rapid enrichment of lysosomes, via immunoisolation, using the endogenous integral lysosomal membrane protein TMEM192, directly from clinical samples and human cells. Isolated lysosomes are intact and suitable for subsequent multimodal omics analyses. To validate the utility of our approach, we employed the tagless LysoIP to enrich lysosomes from peripheral blood mononuclear cells (PBMCs) derived from fresh blood of patients with CLN3 Batten disease, a neurodegenerative LSD. Altogether, the tagless LysoIP provides a framework to study native lysosomes from patient samples, identify novel biomarkers and discover human-relevant disease mechanisms.

2025-01-31 | PXD052082 | Pride

Large scale cerebrospinal fluid proteomics reveals biomarkers of Multiple Sclerosis

Project description:Cerebrospinal fluid (CSF) plays critical roles in clinical diagnostics, offers a window into neuropathological mechanisms and is available at scale. To enable its large-scale proteomics characterization, we developed a high-throughput mass spectrometry-based workflow based on the Orbitrap Astral. This workflow quantifies about 2100 proteins per sample at a throughput of 100 samples per day. We measured 2600 CSF samples across a discovery and replication cohort from patients with multiple sclerosis and related inflammatory CNS conditions as well as neurological controls. Analysis of CSF proteomes yielded a panel of 29 protein biomarkers to identify MS with better diagnostic performance than established clinical CSF markers (QIgG, QAlb, leukocyte count) amongst patients presenting with MS-like symptoms but without CSF-specific oligoclonal bands.

2025-12-10 | PXD064570 | Pride

DSS induced colitis mice Astral-DIA

Project description:This study aims to investigate the protein expression profiles in a murine model of dextran sulfate sodium (DSS)-induced colitis using advanced Astral-DIA quantitative proteomics technology. A total of 12 colon tissue samples were analyzed, including 6 from healthy control mice and 6 from DSS-treated mice with induced colitis. Experimental Design Species: Mus musculus (C57BL/6 strain). Tissue Source: Colon tissues were dissected, snap-frozen in liquid nitrogen, and homogenized to extract proteins. Groups: Control Group: Healthy mice without intervention. DSS Group: Mice subjected to 2.5% DSS administration for 7 days to induce colitis, validated by histopathological assessment.

2025-09-18 | PXD063633 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data